Post-Earnings Coverage - Biogen Idec

LONDON, February 26, 2015 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Investor-Edge.com has issued free post-earnings coverage on Biogen Idec Inc. (NASDAQ: BIIB). On January 29, 2015, the company reported its financial results for Q4 FY14 and full year FY14 (period ended December 31, 2014). Click on http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB to read our free earnings review on Biogen Idec Inc. (Biogen Idec). During Q4 FY14 and full-year FY14, the company's total revenues grew 34% Y-o-Y and 40% Y-o-Y, respectively. Additionally, GAAP net income attributable to Biogen Idec surged 93% Y-o-Y in Q4 FY14 and 58% Y-o-Y in FY14. Our free coverage report can be accessed at:

http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB

Earnings Overview 

During Q4 FY14, Biogen Idec's total revenues were $2.64 billion compared to $1.97 billion in Q4 FY13. The company's Q4 FY14 total revenues came in line with Bloomberg analysts' forecast of $2.64 billion. Biogen Idec's net product revenues increased from $1.61 billion in Q4 FY13 to $2.29 billion in Q4 FY14. The company generated $304.53 million of revenues from unconsolidated joint business in Q4 FY14 compared to $269.42 million in Q4 FY13. Additionally, royalty and corporate partner revenues totaled $31.35 million and $17.81 million, respectively, in Q4 FY14 compared to $60.61 million and $28.74 million, respectively, in Q4 FY13. Free research on BIIB can be downloaded in PDF format at:

http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB

In Q4 FY14, GAAP net income attributable to Biogen Idec increased to $883.46 million, or $3.74 per diluted share, from $457.31 million, or $1.92 per diluted share, in Q4 FY13. Analysts from Bloomberg had expected Q4 FY14 GAAP net income attributable to Biogen Idec of $810.63 million, or $3.42 per diluted share. Moreover, non-GAAP net income attributable to Biogen Idec increased to $965.6 million, or $4.09 per diluted share, in Q4 FY14 from $557.0 million, or $2.34 per diluted share, in Q4 FY13.

For FY14, Biogen Idec's total revenues were $9.70 billion compared to $6.93 billion in FY13. The company's FY14 total revenues came in line with Bloomberg analysts' forecast of $9.70 billion. In FY14, Biogen Idec's net product revenues increased to $8.20 billion from $5.54 billion in FY13. The company reported revenues of $1.20 billion from unconsolidated joint business in FY14, compared to $1.13 billion in FY13. Furthermore, in FY14, royalty and corporate partner contributed $176.70 million and $127.83 million, respectively, to total revenues, compared to $185.69 million and $78.16 million, respectively, in FY13. Sign up and read the free analyst's notes on BIIB at:

http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB

During FY14, GAAP net income attributable to Biogen Idec surged to $2.93 billion, or $12.37 per diluted share, from $1.86 billion, or $7.81 per diluted share, in FY13. Analysts from Bloomberg had expected GAAP net income attributable to Biogen Idec of $2.86 billion, or $12.06 diluted per share, in FY14. Additionally, non-GAAP net income attributable to Biogen came in at $3.28 billion, or $13.83 per diluted share, in FY14 compared to $2.14 billion, or $8.96 per diluted share, in FY13.

As of December 31, 2014, Biogen Idec had cash, cash equivalents and marketable securities of approximately $3.3 billion.

Dr. George A. Scangos, CEO of Biogen Idec, stated that 2015 promises to be another exciting year. The company's focus on novel biology to seek treatments for challenging diseases has shaped its pipeline and business strategy, and management expects that will continue in the future, he added. He also asserted that the company's drive to bring real value to patients, providers and payers has the potential to improve lives, benefit health-care systems and serve the company's shareholders as well.

In its guidance for full-year FY15, Biogen Idec expects revenue to grow approximately by 14% to 16% compared to FY14. The company also anticipates GAAP diluted earnings per share (EPS) to be in the range of $15.45 and $15.85 and Non-GAAP diluted EPS to be between $16.60 and $17.00, in FY15. Further, for FY15, the company expects R&D expense to be approximately 19% to 20% of total revenue and SG&A expense to be approximately 20% to 21% of total revenue. Visit Investor-Edge and access the latest research on BIIB at:

http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB

Stock Performance 

On the day following the earnings release, January 30, 2015, Biogen stock rallied 10.17% to finish the session at $389.16. Since then, the stock has mostly witnessed a positive momentum. On the last close, Wednesday, February 25, 2015, the company's shares ended 1.00% higher at $408.94. The company's shares vacillated between $400.57 and $412.02 during the session. A total of 1.11 million shares were traded which was below its three months average volume of 1.80 million shares. Over the last one month and previous three months, Biogen shares have surged 14.38% and 33.90%, respectively. Further, the stock has gained 18.09% over the past one year. Shares in the company closed above their 50-day and 200-day moving averages of $364.29 and $331.64, respectively. Furthermore, the stock traded at a PE ratio of 33.51 and has a Relative Strength Index (RSI) of 66.24.

Sneak Peek to Corporate Insider Trading 

In the last one month, Biogen has not reported any share transactions by insiders to the U.S. Securities and Exchange Commission (SEC). Complimentary in-depth research on BIIB is available at:

http://get.Investor-Edge.com/pdf/?c=Biogen%20Idec&d=26-Feb-2015&s=BIIB

About Investor-Edge.com 

At Investor-Edge, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Investor-Edge comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.

===============

EDITOR'S NOTES:

===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Investor-Edge